Test Price
600 AED✅ Home Collection Available
Fabry Disease Quantitative Blood Test – DHA Approved – 600 AED
Executive Summary & Core Metrics
Our DHA‑licensed laboratory provides a highly accurate quantitative alpha‑galactosidase A enzyme activity test for early screening of Fabry disease. This first‑line assay delivers 99.9% diagnostic sensitivity, supported by premium logistics and clinical guidance.
- ✓ Accuracy: 99.9% Diagnostic Sensitivity via ISO‑accredited fluorometric methodology
- ✓ Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM – 11 PM
- ✓ Clinical Guidance: Telephonic post‑test counselling and result interpretation
- ✓ Insurance: Direct billing verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
The Fabry Disease Quantitative Blood Test measures alpha‑galactosidase A enzyme activity in whole blood using a fluorometric detection method. It is the recommended first‑line screening test for Fabry disease, an X‑linked lysosomal storage disorder. Early identification allows timely initiation of enzyme replacement therapy and improves patient outcomes.
| Feature | Our DHA‑Approved Test | Alternative (GLA Gene Sequencing) |
|---|---|---|
| Method | Alpha‑Galactosidase A Enzyme Activity (Fluorometric) | Sanger / NGS DNA Analysis |
| Turnaround | 4 Business Days (Sample received by 4 pm daily) | 10–14 Days |
| Sample Requirement | 10 mL Whole Blood (3 EDTA/Heparin Tubes) | 5 mL Whole Blood (1 EDTA Tube) |
| Price | 600 AED | 1,000–1,200 AED |
| Clinical Value | First‑line screening; detects enzyme deficiency; aids treatment monitoring | Confirmatory; identifies specific GLA mutation; carrier testing |
Physician Insight & Safety Protocols
“As a general practitioner with extensive experience in metabolic screening, I can confirm that this quantitative enzyme test is a critical first step in identifying Fabry disease. Accurate results depend on proper sample handling and timely processing. Our team provides compassionate post‑test guidance and ensures patients understand the implications of their results. Please do not alter any prescribed medication without prior consultation with your physician.”
— Dr. Ajay Singh, General Practitioner | DHA Registration ID: 36234132
⚠️ Medication Advisory
Do not discontinue or modify any prescribed medication without discussing with your doctor. This test does not replace medical management or genetic counseling.
Safety Exclusion Criteria & Emergency Red Flags
- Active infection or fever: reschedule test after full recovery.
- Known bleeding disorders or use of high‑dose anticoagulants: inform phlebotomist before collection.
- If you experience sudden chest pain, stroke‑like symptoms (facial drooping, arm weakness), or signs of acute kidney failure before or after sample collection, seek immediate emergency medical care.
Patient FAQ & Clinical Guidance
1. What is the Fabry Disease Quantitative Blood Test, and how is it performed?
This advanced enzyme assay precisely quantifies alpha‑galactosidase A activity from a simple 10 mL blood draw. The sample is collected by a trained phlebotomist either at your home or at a clinic, then transported under refrigerated cold‑chain to our DHA‑licensed laboratory. Fluorescence detection is used to measure enzyme activity, and results are available within 4 business days. This test is the recommended first‑line screening for Fabry disease.
2. How accurate is this enzyme test compared to genetic sequencing for diagnosing Fabry disease?
The enzyme activity test has a diagnostic sensitivity of 99.9% for detecting patients with classic Fabry disease. However, it may show normal activity in some atypical or late‑onset variants. Genetic sequencing (GLA gene) is used as a confirmatory test, especially for carrier detection and for patients with strong clinical suspicion despite normal enzyme levels. Both tests complement each other in a comprehensive diagnostic pathway.
3. Can the home collection service be arranged for children and infants in Dubai?
Yes, our VIP pediatric home collection team is specially trained to handle newborns and children with great care. We follow strict cold‑chain standards (ISO 9001:2015) and offer daily service from 8 AM to 11 PM across all UAE emirates. Contact us on WhatsApp at +971 54 548 8731 to schedule a visit and verify your insurance coverage directly.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
All laboratory operations strictly adhere to the following UAE federal laws and regulations:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring complete confidentiality of your health data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing the secure handling of electronic health records.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – guaranteeing patient safety and clinical accountability.
Our DHA licence (No. 1143) and ISO accreditation confirm our commitment to the highest standards of quality and safety.
Clinical & Logistical Metadata
| Test Name | Fabry Disease Quantitative Blood Test (Alpha‑Galactosidase A Enzyme Activity) |
| Price (AED) | 600 AED |
| Turnaround Time | 4 Business Days (sample received by 4 pm daily) |
| Sample Type / Matrix | 10 mL Whole Blood (3 EDTA/Heparin Tubes) |
| Methodology Used | Fluorometric Enzyme Assay |
| ICD‑10‑CM Code | E75.21 |
| LOINC Code | 33330-0 |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians